GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ilsung Is (XKRX:003120) » Definitions » YoY EBITDA Growth

Ilsung Is (XKRX:003120) YoY EBITDA Growth : 443.73% (As of Sep. 2024)


View and export this data going back to 1985. Start your Free Trial

What is Ilsung Is YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Ilsung Is's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 443.73%.

Ilsung Is's EBITDA per Share for the three months ended in Sep. 2024 was ₩1,551.85.


Ilsung Is YoY EBITDA Growth Historical Data

The historical data trend for Ilsung Is's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ilsung Is YoY EBITDA Growth Chart

Ilsung Is Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.88 -44.95 -79.12 1,806.38 -167.06

Ilsung Is Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112.84 -1,675.41 45.27 144.39 443.73

Ilsung Is YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Ilsung Is's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-2607.298-3887.729)/ | 3887.729 |
=-167.06 %

Ilsung Is's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EBITDA Growth (Q: Sep. 2024 )
=(EBITDA per Share (Q: Sep. 2024 )-EBITDA per Share (Q: Sep. 2023 )) / | EBITDA per Share (Q: Sep. 2023 )) |
=(1551.848-285.408)/ | 285.408 |
=443.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ilsung Is YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Ilsung Is's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Ilsung Is Business Description

Traded in Other Exchanges
N/A
Address
84-gil, 9, Wonhyo-ro, Yongsan-gu, Seoul, KOR, 140-111
Ilsung Is is a South Korean knowledge-based, technology-intensive, research and development industry, The company specializes in the antibiotics field and produces penicillin antibiotics.

Ilsung Is Headlines

No Headlines